eNamptcumab

N/A

Report date: 2025/12/23 10:51:32

Base Information

Drug NameeNamptcumab
Drug Alias NameeNamptcumab (Aqualung Therapeutics)eNamptorALT-100
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionNicotinamide phosphoribosyltransferase inhibitorsToll like receptor 4 inhibitors
TargetsNicotinamide phosphoribosyltransferaseToll like receptor 4
Therapy Area/IndicationsChorioamnionitisRespiratory Distress Syndrome, AdultPulmonary Fibrosis +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAqualung Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesAqualung Therapeutics CorpLeaderMed Health Group Ltd
Inactive CompaniesN/A
Active IndicationsChorioamnionitisRespiratory Distress Syndrome, AdultPulmonary Fibrosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A